via National Cancer Institute
- Test proved able to detect and indicate site of dozens of types of cancer with high accuracy according to recent study
- Dana-Farber joins multi-center trial to provide test results to patients for the first time
In a study involving thousands of participants, a new blood test detected more than 50 types of cancer as well as their location within the body with a high degree of accuracy, according to an international team of researchers led by Dana-Farber Cancer Institute and the Mayo Clinic.
The results, published online today by the Annals of Oncology, indicate that the test – which identified some particularly dangerous cancers that lack standard approaches to screening – can play a key role in early detection of cancer. Early detection can often be critical to successful treatment.
Developed by GRAIL, Inc., of Menlo Park, Calif., the test uses next-generation sequencing to analyze the arrangement of chemical units called methyl groups on the DNA of cancer cells. Adhering to specific sections of DNA, methyl groups help control whether genes are active or inactive. In cancer cells, the placement of methyl groups, or methylation pattern, is often markedly different from that of normal cells – to the extent that abnormal methylation patterns are even more characteristic of cancer cells than genetic mutations are. When tumor cells die, their DNA, with methyl groups firmly attached, empties into the blood, where it can be analyzed by the new test.
“Our previous work indicated that methylation-based tests outperform traditional DNA-sequencing approaches to detecting multiple forms of cancer in blood samples,” said Dana-Farber’s Geoffrey Oxnard, MD, co-lead author of the study with Minetta Liu, MD, of the Mayo Clinic. “The results of this study suggest that such assays could be a feasible way of screening people for a wide variety of cancers.”
In the study, investigators used the test to analyze cell-free DNA (DNA from normal and cancerous cells that had entered the bloodstream upon the cells’ death) in 6,689 blood samples, including 2,482 from people diagnosed with cancer and 4,207 from people without cancer. The samples from patients with cancer represented more than 50 cancer types, including breast, colorectal, esophageal, gallbladder, bladder, gastric, ovarian, head and neck, lung, lymphoid leukemia, multiple myeloma, and pancreatic cancer.
The overall specificity of the test was 99.3%, meaning that only 0.7% of the results incorrectly indicated that cancer was present. The sensitivity of the assay for 12 cancers that account for nearly two-thirds of U.S. cancer deaths was 67.3%, meaning the test could find the cancer two-thirds of the time but a third of the time the test returned a negative result. Within this group, the sensitivity was 39% for patients with stage I cancer, 69% for those with stage II, 83% for those with stage III, and 92% for those with stage IV. The stage I-III sensitivity across all 50 cancer types was 43.9%. When cancer was detected, the test correctly identified the organ or tissue where the cancer originated in more than 90% of cases – critical information for determining how the disease is diagnosed and managed.
“Our results show that this approach to testing cell-free DNA in blood can detect a broad range of cancer types at virtually any stage of the disease, with specificity and sensitivity approaching the level needed for population-level screening,” Oxnard observed. “The test can be an important part of clinical trials for early cancer detection.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Home Quarantined Cancer Patient Dies in UP's Deoria, Samples Taken for Covid-19 Teston May 10, 2020 at 5:02 pm
The health authorities have taken his samples for coronavirus testing, though no infection symptoms were found.
- Early mammography screening lowers risk of developing fatal breast canceron May 10, 2020 at 2:51 pm
Women who go for early mammography screenings lower their risk of developing fatal breast cancer, reseach has found. Scientists in Sweden analysed the records of almost 550,000 women in the country - ...
- Breast Cancer Screening Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Test Type ; End User, and Geographyon May 9, 2020 at 4:50 am
The breast cancer screening was valued at US$ 4,638.63 million in 2019 and is projected to reach US$ 6,209.25 million by 2027; it is expected to grow at a CAGR of 4.8% from 2020 to 2027. Read the full ...
- Post-pandemic surge in cancer diagnoses expected due to delayed screening, doctors sayon May 8, 2020 at 2:29 pm
A surge in cancer diagnoses is expected to hit after the coronavirus pandemic calms down due to a delay in screenings, an event that could be next to slam medical centers, doctors said.
- Lisa Lowenstein, PhD, MPH, on Decision Coaching for Lung Cancer Screeningon May 8, 2020 at 1:21 pm
Furthermore, the implementation of decision coaching for LCS in the LDCT setting did not signiﬁcantly lengthen the time that a patient spends at the clinic," wrote Lisa M. Lowenstein, PhD, MPH, RD, of ...
Go deeper with Google Headlines on:
Go deeper with Bing News on:
Cancer blood test
- We Just Won a Skirmish in the War on Canceron May 10, 2020 at 5:00 am
Recent data show that mammograms and prostate cancer screenings have led people to have unnecessary surgeries and other invasive procedures for cancers that were unlikely to harm them. Such tests can ...
- Blood test seems an effective aid in cancer screeningon May 7, 2020 at 5:05 pm
NEW YORK (Reuters Health) - A multicancer blood test appears to have met its initial goal of being an effective addition to standard screening for cancer, in a study of nearly 10,000 women. The aim of ...
- Blood Test Promising as Colorectal Cancer Screenon May 7, 2020 at 10:36 am
Testing blood for three distinct colorectal cancer (CRC) markers showed perfect sensitivity and 90% specificity for detecting malignancy in a preliminary study, researchers said. The test involves ...
- Grail's 4th funding round nets $390M for its cancer-seeking blood teston May 7, 2020 at 4:30 am
Grail has secured its fourth nine-digit-plus financing round, bringing its total funding to nearly $2 billion as it looks to complete the clinical testing of its cancer-seeking blood test.
- This Blood Test Detects Cancer In People Even Without Symptomson May 5, 2020 at 7:45 pm
Researchers at Johns Hopkins University have developed a new blood test that could help people detect several types of cancer through a single screening.